Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. by McQuaid, F, Snape, M, John, T, Kelly, S, Robinson, H, Yu, L, Toneatto, D, D'Agostino, D, Dull, P, Pollard, A

“…We investigated the persistence of antibodies in 5-year-old children 18-20 months after their last dose (at about 3.5 years of age). …”

The B-cell response to a primary and booster course of MenACWY-CRM₁₉₇ vaccine administered at 2, 4 and 12 months of age. by Blanchard-Rohner, G, Snape, MD, Kelly, D, O'Connor, D, John, T, Clutterbuck, E, Ohene-Kena, B, Klinger, C, Odrljin, T, Pollard, A

“…For MenC and CRM197, the antigens with the highest number of B-cells at 5 months, there was a definite (p ≤0 .02) but weak correlation with antibody persistence at 12 months. …”

Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age. by McQuaid, F, Snape, MD, John, T, Kelly, S, Robinson, H, Houlden, J, Voysey, M, Toneatto, D, Kitte, C, Dull, P, Pollard, A

“…METHODS: Sera were obtained from 3 groups of 5-year-old children previously immunized at 6, 8, 12 and 40 months with either 4CMenB or rMenB (which lacks the outer membrane vesicle of 4CMenB) or at 40 and 42 months with 4CMenB only. …”

The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age by Blanchard-Rohner, G, Snape, MD, Kelly, D, O'Connor, D, John, T, Clutterbuck, E, Ohene-Kena, B, Klinger, C, Odrljin, T, Pollard, A

“…For MenC and CRM197, the antigens with the highest number of B-cells at 5 months, there was a definite (p≤0.02) but weak correlation with antibody persistence at 12 months. …”

Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. by Pace, D, Khatami, A, McKenna, J, Campbell, D, Attard-Montalto, S, Birks, J, Voysey, M, White, C, Finn, A, Macloed, E, Faust, S, Kent, A, Heath, P, Borrow, R, Snape, M, Pollard, A

“…PARTICIPANTS: Healthy infants aged 6-12 weeks followed up until age 24 months. INTERVENTIONS: In the priming phase of the trial 509 infants were randomised in a 10:10:7:4 ratio into four groups to receive either a single MenC-cross reacting material 197 (CRM) dose at 3 months; two doses of MenC-CRM at 3 and 4 months; a single MenC-polysaccharide-tetanus toxoid (TT) dose at 3 months; or no MenC doses, respectively. …”

Persistence of bactericidal antibodies following infant serogroup B meningococcal immunization (4CMenB) and booster dose response at 12, 18 or 24 months of age by Snape, M, Pollard, A, Voysey, M, Finn, A, Bona, G, Esposito, S, Principi, N, Diez-Domingo, J, Sokal, E, Kieninger, D, Prymula, R, Dull, P, Kohl, I, Barone, M, Wang, H, Toneatto, D

“…Participants previously receiving 4CMenB with routine vaccines at 2,4,6 or 2,3,4 months (246Con and 234Con) or at 2,4,6 months intercalated with routine vaccines (246Int) received a booster dose at 12, 18 or 24 months. 4CMenB-naïve ‘Control’ participants aged 12, 18 or 24 months received two doses of 4CMenB two months apart. …”

Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. by Snape, MD, Klinger, C, Daniels, E, John, T, Layton, H, Rollinson, L, Pestridge, S, Dymond, S, Galiza, E, Tansey, S, Scott, D, Baker, SA, Jones, T, Yu, L, Gruber, W, Emini, E, Faust, SN, Finn, A, Heath, P, Pollard, A

“…METHODS: Two hundred eighty-six healthy infants received PCV13 or the 7-valent-pneumococcal conjugate vaccine (PCV7) at 2, 4, and 12 months of age, alongside a serogroup C meningococcal (MenC) vaccine (2 and 4 months of age), DTaP-IPV-Hib (2, 3, and 4 months), and a Hib-MenC vaccine (12 months). …”

Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants. by Khatami, A, Snape, MD, Ohene-Kena, B, Young, K, Oeser, C, Michaelis, L, Macleod, E, Smee, H, Van Der Meeren, O, Leyssen, M, Caubet, M, Yu, L, Heath, P, Faust, SN, Finn, A, Pollard, A

“… AIM: To test for immunologic noninferiority of antibody responses to Hib and MenC using a 6-in-1 combination vaccine (DTPa-IPV/Hib-MenC-TT) compared with DTPa-IPV-Hib plus MenC-CRM197, before and after a 12-month Hib-MenC-TT booster. METHODS: Pragmatic open-label, randomized, multicenter, UK study. "6-in-1" group received DTPa-IPV/Hib-MenC-TT at 2, 3 and 4 months; control group received DTPa-IPV-Hib at 2, 3 and 4 months and MenC-CRM197 at 3 and 4 months. …”

Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. by Snape, MD, Philip, J, John, T, Robinson, H, Kelly, S, Gossger, N, Yu, L, Kittel, C, Toneatto, D, Dull, P, Pollard, A

“…METHODS: In this extension study, SBA titers were evaluated before and after a booster dose of rMenB or 4CMenB at 40 months of age. MenB vaccine naïve age-matched children served as a control group. …”

Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: A follow-on study to a randomized clinical trial by Snape, MD, Philip, J, John, T, Robinson, H, Kelly, S, Gossger, N, Yu, L, Kittel, C, Toneatto, D, Dull, P, Pollard, A

“…Methods: In this extension study, SBA titers were evaluated before and after a booster dose of rMenB or 4CMenB at 40 months of age. MenB vaccine naïve age-matched children served as a control group. …”

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial. by Iro, M, Snape, M, Voysey, M, Jawad, S, Finn, A, Heath, P, Bona, G, Esposito, S, Diez-Domingo, J, Prymula, R, Odueyungbo, A, Toneatto, D, Dull, P, Pollard, A, European Men B Vaccine Study Group

“…We assessed persistence of human complement serum bactericidal activity (hSBA) following a fourth dose administered at 12, 18 or 24 months and characterised the antibody response to a fifth dose administered at 4 years of age.…”

Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial. by Hamaluba, M, Kandasamy, R, Upreti, S, Subedi, G, Shrestha, S, Bhattarai, S, Gurung, M, Pradhan, R, Voysey, M, Gurung, S, Pradhan, S, Thapa, A, Maharjan, R, Kiran, U, Kerridge, S, Hinds, J, van der Klis, F, Snape, M, Murdoch, D, Kelly, S, Kelly, D, Adhikari, N, Thorson, S, Pollard, A

“…The primary outcome measure was to determine the proportion of participants in the 2+1 group at age 10 months with specific IgG for serotypes 1, 5, and 14 of at least 0·2 μg/mL in the per-protocol population. …”

Safety and immunogenicity of AS03 B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study by Waddington, C, Walker, W, Oeser, C, Reiner, A, John, T, Wilkins, S, Casey, M, Eccleston, P, Allen, R, Okike, I, Ladhani, S, Sheasby, E, Hoschler, K, Andrews, N, Waight, P, Collinson, A, Heath, P, Finn, A, Faust, SN, Snape, MD, Miller, E, Pollard, A

“…Children were grouped by age: 6 months-<3 years (younger group) and 3-<13 years (older group). …”

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. by Waddington, C, Walker, W, Oeser, C, Reiner, A, John, T, Wilkins, S, Casey, M, Eccleston, P, Allen, R, Okike, I, Ladhani, S, Sheasby, E, Hoschler, K, Andrews, N, Waight, P, Collinson, A, Heath, P, Finn, A, Faust, SN, Snape, MD, Miller, E, Pollard, A

“…Children were grouped by age: 6 months-<3 years (younger group) and 3-<13 years (older group). …”

Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]. by Iro, M, Snape, M, Voysey, M, Jawad, S, Finn, A, Heath, P, Bona, G, Esposito, S, Diez-Domingo, J, Prymula, R, Odueyungbo, A, Toneatto, D, Dull, P, Pollard, A, European Men B Vaccine Study Group

Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. by Waddington, C, Andrews, N, Hoschler, K, Walker, W, Oeser, C, Reiner, A, John, T, Wilkins, S, Casey, M, Eccleston, P, Allen, R, Okike, I, Ladhani, S, Sheasby, E, Waight, P, Collinson, A, Heath, P, Finn, A, Faust, S, Snape, M, Miller, E, Pollard, A

“… OBJECTIVE: To evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children aged 6 months to 12 years. DESIGN: Multicentre, randomised, head-to-head, open-label trial. …”

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. by Snape, MD, Perrett, K, Ford, K, John, T, Pace, D, Yu, L, Langley, J, McNeil, S, Dull, P, Ceddia, F, Anemona, A, Halperin, SA, Dobson, S, Pollard, A

“…All received MenACWY at 12 months. Canadian infants received MenACWY at 2, 4, and 6 months or 2 and 4 months; at 12 months they received MenACWY, a plain tetravalent polysaccharide vaccine, or no vaccine. …”

Unveiling the risk period for death after respiratory syncytial virus Illness in young children using a self- controlled case series design by Li, Y, Campbell, H, Nair, H, Reeves, RM, Douglas, A, Meijer, A, Fischer, TK, Heikkinen, T, Giaquinto, C, Swanson, K, Stoszek, S, Leach, A, Demont, C, Gallichan, S, Aerssens, J, Beutels, P, Bont, L, Pollard, A, Openshaw, P, Abram, M, Rosen, B, Molero, E

“…Further studies are warranted to assess the mortality risk beyond the first month after RSV illness episode.</p>…”

Schedules for pneumococcal vaccination of preterm infants: an RCT by Kent, A, Ladhani, S, Andrews, N, Scorrer, T, Pollard, A, Clarke, P, Hughes, S, Heal, C, Menson, E, Chang, J, Satodia, P, Collinson, A, Faust, S, Goldblatt, D, Miller, E, Heath, P, PUNS Study Group

“…Our goal was to assess the immunogenicity of 3 commonly used 13-valent pneumococcal conjugate vaccine (PCV13) priming schedules in premature infants and their response to a 12-month booster dose. METHODS: Premature infants (&lt;35 weeks' gestation) were randomized to receive PCV13 at 2 and 4 months (reduced schedule); 2, 3, and 4 months (accelerated schedule); or 2, 4, and 6 months (extended schedule). …”

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. by Read, R, Baxter, D, Chadwick, DR, Faust, SN, Finn, A, Gordon, S, Heath, P, Lewis, D, Pollard, A, Turner, D, Bazaz, R, Ganguli, A, Havelock, T, Neal, K, Okike, I, Morales-Aza, B, Patel, K, Snape, MD, Williams, J, Gilchrist, S, Gray, S, Maiden, M, Toneatto, D, Wang, H, McCarthy, M

“…INTERPRETATION: Although we detected no significant difference between groups at 1 month after vaccine course, MenACWY-CRM and 4CMenB vaccines reduced meningococcal carriage rates during 12 months after vaccination and therefore might affect transmission when widely implemented. …”